A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission

The information below is intended for medical professionals.  For patient information please click here and here

Study design/Summary: This is a 2 arm, phase II, multicentre, randomised clinical trial in adult patients with Acute Lymphoblastic Leukaemia (ALL) in complete remission (CR) undergoing a allogeneic stem cell transplant (SCT) comparing the novel conditioning regimen of TBI and cyclophosphamide with the standard conditioning of fludarabine/melphalan/alemtuzumab (FMA)

Objectives: The primary objectives of this study are to compare the disease free survival at two years of patients with ALL after a TBI and cyclophosphamide stem cell transplant with that of patients transplanted using the FMA conditioning regimen. There are also other objectives in addition to the primary one which include; overall survival; cumulative incidence of disease relapse, non-relapse mortality; incidence of grade 2-4 acute graft-versus-host-disease (GvHD), incidence of chronic GvHD of any grade, occurrence and severity of veno-occlusive disease (VOD); duration of hospitalisation in the first year; quality of file, full donor chimerism at day 100 and TBI related symptomatic pulmonary toxicity following allogenic SCT.

Centres: 22 IMPACT centres

Target number of patients: 247 patients

Patient population: Patients with ALL who are suitable to undergo an allogenic SCT

Sponsorship/Funding: University of Birmingham, funded by the IMPACT network

Trial Status: Closed to recruitment/In follow-up

Trial Contacts:

Start date: 17 September 2018

Duration: 7 years

If you are a patient and interested in taking part in a clinical trial, please speak with your consultant who will be able to offer you further information and discuss whether it is suitable for you. A referral from your medical team would be required in order to consider you for treatment on a clinical trial.